Physician profile
Robert A Krause
NPI 1346231388
$1,682.02
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $471 · 2020: $192 · 2021: $199 · 2022: $206 · 2023: $329 · 2024: $285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $613.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $670.25 | 2019-2024 | Arexvy, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $282.82 | 2021-2024 | |
| Abbvie INC. | $239.24 | 2022-2023 | |
| Amgen INC. | $128.34 | 2019 | |
| Pfizer INC. | $108.85 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $83.27 | 2019 | |
| Novartis Pharmaceuticals Corporation | $65.95 | 2019 | |
| Dexcom, INC. | $28.82 | 2024 | Dexcom G6 Transmitter |
| Medtronic, INC. | $28.13 | 2022 | |
| Neurocrine Biosciences, INC. | $16.79 | 2023 | Ingrezza |
| Xeris Pharmaceuticals, INC. | $15.24 | 2023 | Keveyis |
| Merck Sharp & Dohme LLC | $14.32 | 2024 | Capvaxive, Gardasil, Gardasil 9 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Krause listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.